Results 91 to 100 of about 23,326 (221)

Re‐engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis—A mixed methods study

Skin Health and Disease
Background Targeted biologic therapies have revolutionised the treatment of severe atopic dermatitis (AD). Objectives To assess effects of dupilumab on patient re‐engagement, quality of life (QOL), and burden of treatment (BOT) in severe AD.
Emma Porter, Cathal O’Connor, Michelle Murphy   +2 more
doaj   +1 more source

Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach

Clinical Case Reports
The off‐label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab‐induced erythrodermic psoriasiform dermatitis.
Joe Khodeir, Maya Habre
doaj   +1 more source

Suspensión de dupilumab en dermatitis atópica. ¿es una opción la suspensión? Seguimiento de 12 casos

Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Antecedentes: Dupilumab es el primer tratamiento biológico aprobado para la dermatitis atópica (DA) moderada a severa con excelente perfil de seguridad y eficacia pero hasta el momento con poca literatura sobre la duración de tratamiento.   Objetivo:
Mirian Casas-Vargas, Cindy Cáceres-Salamanca, María Fernanda Ordóñez-Rubiano   +2 more
doaj   +1 more source

BASELINE CHARACTERISTICS OF PATIENTS WITH ASTHMA AND PRIOR SYSTEMIC CORTICOSTEROID USE INITIATING DUPILUMAB IN REAL-WORLD CLINICAL PRACTICE IN THE RAPID REGISTRY [PDF]

, 2023
Njira Lugogo, Enrico Heffler, Vicente Plaza, OLE HILBERG, CHANGMING XIA, Scott D. Nash, NAMI PANDIT-ABID, JUBY A JACOB-NARA, Harry Sacks, PAUL J ROWE, YAMO DENIZ, MEGAN HARDIN, XAVIER SOLER   +12 more
openalex   +1 more source

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Journal of Dermatological Treatment
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic
C. Grote, F. Zirkenbach, J. N. Wagner, M. Augustin   +3 more
doaj   +1 more source

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis

, 2020
И. С. Крысанов, В. С. Крысанова, О. И. Карпов, V. Yu. Ermakova   +3 more
openalex   +2 more sources

The microbiome in patients with atopic dermatitis. [PDF]

, 2019
As an interface with the environment, the skin is a complex ecosystem colonized by many microorganisms that coexist in an established balance. The cutaneous microbiome inhibits colonization with pathogens, such as Staphylococcus aureus, and is a crucial ...
Gallo, Richard L, Irvine, Alan D, Kong, Heidi H, Luger, Thomas, Naik, Shruti, Paller, Amy S, Scharschmidt, Tiffany C, Seed, Patrick   +7 more
core  

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study

BMC Pediatrics
Background Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling.
Mohammed Hasosah, Ghassan Sukkar, Asharf AlSahafi, Ali Zaidan, Nouf Ghous, Abdulmajed Alshahrani, Ziyad Al Zahrani, Naif Hasosah, Mansour Qurashi, Loie Goronfolah, Ali Alsharief, Nagla Kamal   +11 more
doaj   +1 more source

Omalizumab en práctica clínica dermatológica. Indicaciones, mecanismo de acción y factores predictivos de respuesta [PDF]

, 2019
El Omalizumab es un anticuerpo monoclonal anti-IgE aprobado para el tratamiento del asma y de la urticaria crónica idiopática refractaria al tratamiento con antihistamínicos H1.
Fernández Gutiérrez, Eva, García-Peñuela Arrechea, Íñigo   +1 more
core  

High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis [PDF]

, 2023
Ao Wang, Yuan Zhou, Yang Luo, Yingxia Gao, Jingsi Chen, Wei Li, Xiaoyan Luo, Xu Yao   +7 more
openalex   +1 more source